Source: Annual Congress 2002 - Biological disease markers in airways and parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Fujimoto, E. C. Gabazza, O. Hataji, H. Yuda, Y. Adachi, O. Taguchi (Tsu, Japan). Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease. Eur Respir J 2002; 20: Suppl. 38, 3620

Member's Comments

No comment yet.

Related content which might interest you: Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 83s Year: 2003 Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002 Thrombin activatable fibrinolytic inhibitor in sera from NSCLC patients Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005 Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 461s Year: 2005 Role of thrombin-activatable fibrinolysis inhibitor in lipopolysaccharide-induced acute lung injury Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018 Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009 Role of thrombin-activatable fibrinolysis inhibitor in bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009 A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2012; 40: 1475-1482 Year: 2012 Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS Source: Annual Congress 2012 - How to use technology to provide better critical care Year: 2012 Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation Source: Eur Respir J 2007; 30: 423-428 Year: 2007 Increased intraalveolar level of soluble endothelial protein C receptor in patients with interstitial lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 319s Year: 2004 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Elevation of neutrophil collagenase (MMP-8) and elastase during COPD exacerbation Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008 Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003 Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema Source: Eur Respir J 2002; 19: 1050-1057 Year: 2002 The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Measurement of tumour necrosis factor converting enzyme (TACE) activity on alveolar macrophages from healthy subjects and subjects with inflammatory lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 417s Year: 2002 The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005